

0.3 mg/ml Solution for injection

- Long-term post-operative analgesia
- Partial µ-receptor agonist with fewer sedative/adverse effects than other opioids
- Longer-lasting action than methadone
- Little effect on gastrointestinal motility
- Onset of analgesic effect after approximately 30 minutes





C.N. 589520.8

BUPRELAB 0,3 mg/ml

Buprenorfina


LABIANA

(10 ml)



PRESYNAPTIC NEURON





COMPOSITION PER ML

Buprenorphine 0.3 mg

INDICATIONS FOR USE

- Post-operative analgesia in dogs and cats.
- Potentiation of the sedative effects of centrally-acting agents in dogs.

DOSAGE AND ADMINISTRATION METHODS

Dogs:

Post-operative analgesia: 0.03-0.06 ml Buprelab per kg b.w. IM or IV. Repeat if necessary after 3-4 hours with 0.03 ml Buprelab per kg b.w. or after 5-6 hours with 0.06 ml Buprelab per kg b.w. Potentiation of sedation: 0.03-0.06 ml Buprelab per kg b.w. IM or IV.

Cats:

Post-operative analgesia: 0.03-0.06 ml Buprelab per kg b.w. IM or IV. Repeat if necessary after 1-2 hours.

CONTRAINDICATIONS

- Do not administer via intrathecal or epidural route.
- Do not use pre-operatively for Caesarean sections.
- Do not use in animals with known hypersensitivity to the active substance or to any of the excipients.

ADVERSE REACTIONS

Dogs may infrequently experience salivation, bradycardia, hypothermia, agitation, dehydration and miosis, and on rare occasions hypertension and tachycardia.

- · Cats may commonly experience mydriasis and signs of euphoria (excessive purring, pacing, rubbing), which will usually resolve after 24 hours.
- When used for analgesic purposes, sedation occurs rarely. However, this may occur if higher than recommended doses are administered.
- Local discomfort or pain at the injection site, resulting in vocalisation, may occur very rarely. This effect is normally transient.

USE DURING GESTATION OR LACTATION

This veterinary medicine shall not be used pre-operatively for Caesarean section due to risk of respiratory depression.

Not recommended for use during lactation.

Use only in accordance with the benefit/risk assessment by the treating veterinarian.

INTERACTION WITH OTHER MEDICINES

Buprenorphine may cause drowsiness, which may be potentiated by other centrallyacting agents including tranquillisers, sedatives and hypnotics.

Buprenorphine has been used with acepromazine, alphaxalone/alphadalone, atropine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol, sevoflurane, thiopentone and xylazine. When used in combination with sedatives. its depressive effects on heart rate and respiration may be increased.

PRESENTATIONS

Box containing 110 ml vial Registration no.: 4030 ESP. Medicine subject to veterinary prescription. Administration under veterinary monitoring or supervision.

